Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 24 for Cholangiocarcinoma (bile duct cancer)

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  3. A Phase I, Multi-Center, Open Label, Dose De-escalation and Expansion Study of Gemcitabine and Cisplatin with AG120 or Pemigatinib for Advanced Cholangiocarcinoma

    Rochester, MN, Scottsdale/Phoenix, AZ

  4. PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

    Rochester, MN

  5. A Study to Evaluate the Effectiveness and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

    Rochester, MN, Jacksonville, FL

  7. A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study to Evaluate Precision Pharmacogenomics in Cancer Patients

    Scottsdale/Phoenix, AZ

  10. A Study of MEDI5395 in Combination With Durvalumab in Subjects with Select Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer